Bal Pharma Limited

NSE BALPHARMA.NS

Bal Pharma Limited Shareholders' Equity for the year ending March 31, 2024: USD 8.31 M

Bal Pharma Limited Shareholders' Equity is USD 8.31 M for the year ending March 31, 2024, a 7.04% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Bal Pharma Limited Shareholders' Equity for the year ending March 31, 2023 was USD 7.76 M, a 0.52% change year over year.
  • Bal Pharma Limited Shareholders' Equity for the year ending March 31, 2022 was USD 7.72 M, a 5.51% change year over year.
  • Bal Pharma Limited Shareholders' Equity for the year ending March 31, 2021 was USD 7.32 M, a 5.18% change year over year.
  • Bal Pharma Limited Shareholders' Equity for the year ending March 31, 2020 was USD 6.96 M, a -27.46% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
SV Wall Street
NSE: BALPHARMA.NS

Bal Pharma Limited

CEO Mr. Shailesh Dheerajmal Siroya
IPO Date May 8, 2006
Location India
Headquarters Lakshmi Narayan Complex
Employees 868
Sector Consumers Staples
Industries
Description

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Similar companies

BIL.NS

Bhartiya International Ltd.

USD 7.33

-4.47%

BSL.NS

BSL Limited

USD 2.33

0.98%

ALPA.NS

Alpa Laboratories Limited

USD 1.34

0.92%

AURIONPRO.NS

Aurionpro Solutions Limited

USD 17.27

-2.09%

StockViz Staff

February 2, 2025

Any question? Send us an email